Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;20(3):251-5.
doi: 10.5114/wo.2016.61569. Epub 2016 Aug 4.

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma

Evrim Metcalfe  1 , Ozden Karaoglanoglu  2 , Emine Akyazici  2
Affiliations

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma

Evrim Metcalfe et al. Contemp Oncol (Pozn). 2016.

Abstract

Introduction: Although the recommended optimal treatment of glioblastoma multiforme (GBM) is adjuvant chemoradiotherapy, trials in GBM have excluded patients older than 70 years. In this study, we aimed to assess overall survival (OS) and prognostic factors in elderly patients (≥ 70 years) with newly diagnosed GBM treated with radiotherapy (RT) ± concurrent/adjuvant temozolomide (TMZ).

Material and methods: Inclusion criteria were patients ≥ 70 years, pre-RT Karnofsky performance status (KPS) ≥ 60, and time between diagnosis and start of RT ≤ 2 months. A total of 40 patients aged ≥ 70 years, 12 female and 28 male, treated between January 2004 and December 2012, were evaluated. Median age was 73.5 years (range, 70-83 years). The median RT dose was 60 Gy (range, 30-62 Gy). Twenty-one (52.5%) received concurrent TMZ, and of those 12 (30%) went on to receive adjuvant TMZ.

Results: The median OS was 7 months (95% CI: 5.45-8.54). One- and two-year OS for the whole cohort was 38% and 16%, respectively. Sex, type of surgery, tumor size, and RT dose did not significantly affect the OS. Presence of concurrent TMZ (p < 0.005) and presence of adjuvant TMZ (p < 0.001) were associated with longer OS in our cohort.

Conclusions: RT ± TMZ seems to be a well-tolerated treatment in patients ≥ 70 years with GBM. Even though no superiority was found between conventional or hypofractionated RT regimens (p = 0.405), the addition of concurrent and adjuvant TMZ to RT increased the OS in our study.

Keywords: elderly; glioblastoma; prognostic factors; radiotherapy; temozolomide.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier plots are shown relationship between overall survival (OS) and temozolomide (TMZ) in elderly patients with glioblastoma multiforme (GBM): A) Kaplan-Meier plot comparing OS in only radiotherapy (RT) vs. RT plus concurrent TMZ groups (p < 0.005). B) Kaplan-Meier plot comparing OS in adjuvant TMZ vs. follow-up after RT + TMZ groups (p < 0.001)
See this image and copyright information in PMC

References

    1. Stark AM, Stepper W, Mehdorn HM. Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. Eur J Cancer Care (Engl) 2010;19:39–44. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. - PubMed
    1. Oh SW, Jee TK, Kong DS, Nam DH, Lee JI, Seol HJ. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients. Acta Neurochir (Wien) 2014;156:641–51. - PubMed
    1. Niyazi M, Schwarz SB, Suchorska B, Belka C. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol. 2012;188:154–9. - PubMed
    1. Fiorentino A, De Bonis P, Chiesa S, Balducci M, Fusco V. Elderly patients with glioblastoma: the treatment challenge. Expert Rev Neurother. 2013;13:1099–105. - PubMed

LinkOut - more resources